By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
Patient access today not tomorrow.
We are poised to create fastracks using Real World Evidence. Not only helping patients suffering the most in society but also generating revenue through medical reimbursement.
Executive Summary
Albert Labs is a laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies through accelerated regulatory approval pathways.
The company’s core focus is treating patients with urgent and unmet needs; these are critical mental health indications, that are not being addressed by big pharma, beginning with cancer-related anxiety, through trials in the UK and Scandinavia.
Albert will be the first psychedelics company to use an accelerated pathway, known as Real-World Evidence (RWE) studies, to swiftly provide access to patients in need. Albert Labs will own the study data to improve and protect their psychedelic-based therapies.
The company has an asset-light business model as it leverages existing clinical infrastructure and patient pools through a collaboration among research institutions, medical centers and reimbursement networks. Albert will scale these collaborations in the UK and across Europe to; generate revenue rapidly, ensure research institutions are published to attract more funding and provide patients with faster access to treatment solutions. Additional studies will be run to develop protected therapies that address other niche mental health indications.
Albert has submitted applications for a psychedelics research and dealer’s licenses which will allow the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline in its lab in Burnaby, BC Canada. These Health Canada licenses will also allow the company to import/export, test, and conduct R&D on these controlled substances.
"We aim to provide relief to
cancer patients suffering from
cancer related depression & anxiety while generating a
steady revenue stream and
creating shareholder value.”
Who is Albert Hofmann's >>
History
Albert Hofmann, (born Jan. 11, 1906, Switzerland.—died April 29, 2008 ), a Swiss chemist who discovered the psychedelic drug lysergic acid diethylamide (LSD), which he first synthesized in 1938 by isolating compounds found in ergot (Claviceps purpurea), a fungus affecting rye.
Upon graduation he began work at Sandoz Laboratories in Basel, where he was assigned to a program developing methods for synthesizing compounds found in medicinal plants. It was there, while testing the analeptic (stimulant) properties of ergot derivatives, that Hofmann stumbled upon LSD-25 (the 25th such derivative tested) in 1938.
Hofmann’s initial discovery was set aside deemed pharmacologically uninteresting, and underwent no further tests. 5 years later, April 1943, he returned to his earlier research on the compound. and after accidentally absorbing a small amount of LSD-25, he experienced dreamlike hallucinations. Intrigued Hoffman continued his study purposely ingested the drug numerous times, and concluded that it could be of significant use in psychiatric treatment.
He spent years investigating LSD’s hallucinogenic properties in the belief that the drug would one day be useful in the therapeutic treatment in psychiatry. During the 1960’s the recreational use came to define LSD. Hofmann maintained and defended that the drug, when taken under controlled circumstances and could prove useful in a psychiatric context an argument that he conveyed in his 1979 book LSD: My Problem Child.
Let us tell you more.
We will email you to start the conversation.
Supporting mental health and more.
Current mental health treatments are decades old, relatively ineffective and can come with severe side effects. New approaches to antidepressants have failed and major pharma has abandoned R&D.
+500 Million People
Suffer from anxiety and depression disorders worldwide.
Unmet medical need
With only 1 in 3 patients responding to treatment within 12 weeks.